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Summary
Background: To better understand symptoms experienced by patients infected with
chronic hepatitis C virus (HCV), valid and reliable patient-reported outcome (PRO)
measures are needed.
Aim: To assess the reliability and validity of 10 patient-reported outcomes measure-
ment information system (PROMIS) measures and the Headache Impact Test-6
(HIT-6) in a large national sample of patients with HCV.
Methods: Pre-treatment data from 961 patients with HCV starting direct acting
antiviral therapy at 11 U.S. liver centers were analyzed. Internal reliability was evalu-
ated using Cronbach’s alpha coefficient; frequency distributions were examined for
floor and ceiling effects; structural validity was investigated via item-response-the-
ory models; convergent validity was evaluated using correlations with theoretically-
similar items from the HCV-PRO and memorial symptom assessment scale (MSAS);
and known-groups validity was investigated by observing PRO differences by liver
disease status and number of comorbidities.
Results: The HIT-6 and the majority of the PROMIS measures yielded excellent reli-
ability (alphas ≥ 0.87). Ceiling effects were infrequent ( < 4%), while 30%-59% of
patients reported no symptoms (floor effects). The data supported structural validity
of the HIT-6 and most PROMIS measures. The PROMIS measures showed moder-
ate to strong correlations with theoretically-similar items from the HCV-PRO and
MSAS (0.39-0.77). Trends were observed between worse PRO scores and advanced
cirrhosis and greater number of comorbidities, lending support for known-groups
validity.
Conclusions: The psychometric properties of the HIT-6 and PROMIS measures per-
formed satisfactorily in this large cohort of patients with HCV starting direct acting
antiviral therapy. Opportunities exist for further refinement of these PROs. Evalua-
tion of performance over time and in under-represented subgroups is needed.
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publication after full peer-review.
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1 | INTRODUCTION
People living with chronic hepatitis C virus (HCV) infection often
report a broad array of physical and mental symptoms1-4 including
but not limited to, fatigue, musculoskeletal pain, poor appetite, nau-
sea, abdominal pain, cognitive impairment, depression, anxiety, irri-
tability and sleep distubance.1,5 Numerous studies have investigated
health related quality of life (HRQOL) in patients living with chronic
HCV.6,7 However, a comprehensive quantitative analysis of patients’
experiences of specific symptoms that may be associated with HCV
has not been conducted.5
The new direct acting antiviral (DAA) therapies to treat HCV are
very well tolerated compared to previous treatments; nonetheless,
they can still cause side effects, such as fatigue, nausea, and head-
ache.8-11 Thus far, our understanding of patients’ experiences with
DAA therapy has been limited to data derived from industry-spon-
sored DAA trials.12,13 Those studies provided very useful information
regarding the effects of DAAs on patients’ HRQOL, work productiv-
ity, and fatigue.14 However, no other symptom experiences have
been evaluated from the patients’ perspective during DAA therapy.
The impact of disease, treatment and viral cure on peoples’ lives
is nearly impossible to understand without direct input from patients
themselves. Patients’ experiences are evaluated using patient-
reported outcome (PRO) measures, defined as “any report of the sta-
tus of a patient’s health condition that comes directly from the
patient, without interpretation of the patient’s response by a clini-
cian or anyone else.”15 PRO measures are the best way to capture
patients’ experiences about how a disease, its treatment, or cure
affects their lives in a meaningful way.
A recent literature review identified 22 key PRO concepts that
were found to be important to people living with HCV in qualita-
tive studies.5 The majority of these concepts are specific symptoms
such as depression, fatigue, anxiety, cognitive dysfunction, muscu-
loskeletal pain, irritability, sleep problems, lack of appetite, and gas-
trointestinal symptoms. Many of these specific symptoms that
concern patients have received inadequate attention in HCV clinical
studies. Of the 18 PRO measures utilized in HCV clinical studies,
only four have actually been developed or validated in the HCV
population, three of which are broad HRQOL measures which are
not designed to thoroughly measure specific symptoms or side
effects.6,16,17
In response to increasing recognition of the importance of evalu-
ating patients’ experiences of illness and treatment, the National
Institutes of Health Patient-Reported Outcomes Measurement Infor-
mation System (PROMIS) initiative has developed a comprehensive
well-evaluated set of self-report tools, some of which measure speci-
fic symptoms.18,19 PROMIS measures have been used in a few hepa-
tology studies,20,21 one of which validated several instruments
delivered via a computerized adaptive testing system in patients with
cirrhosis.20 PROMIS measures have several advantages over other
PRO measures: items were developed using qualitative and quantita-
tive methods; surveys are designed to measure a single symptom
and not overlap with others; surveys are brief (4-8 items); and scores
can be compared across other health conditions and populations.
In the current study, we evaluated the reliability and validity of
several PROMIS short form measures and the Headache Impact Test
(HIT-6), a symptom not assessed by PROMIS.22 The specific aims of
the study were to evaluate the following psychometric properties:
(1) internal reliability; (2) floor and ceiling effects; and (3) construct
validity (structural validity, convergent validity, and known-groups
validity).
2 | MATERIALS AND METHODS
2.1 | Parent study
The psychometric properties of PROMIS measures were evaluated
using baseline data from the Patient-Reported Outcomes Project of
HCV-TARGET (“PROP UP”) (Clinical trial.gov: NCT02601820). A
complete description of the PROP UP study is reported elsewhere.23
Briefly, PROP UP is a multi-site, longitudinal, observational, study
designed to enroll 1,600 patients with chronic HCV infection at 11
U.S. liver centers to characterize patients’ experiences before, during
and after DAA therapy. At five time points during the study, patients
completed multiple PRO measures in the clinic, via email link to a
data capture system, or through phone interview with trained staff
from a centralized call center. Completion of surveys at each time
point averaged 25 minutes (range: 15-45 minutes). Recruitment
began in January 2016. All sites received approval from their local
Institutional Review Board prior to recruitment.
2.2 | Study design
Data from baseline assessments were used to conduct a cross-sec-
tional study of the reliability and validity of the HIT-6 and 10 PRO-
MIS measures. Patients who consented and completed baseline
surveys were included in this analysis.
2.3 | Research participants
Inclusion/exclusion criteria have been previously reported.23 Briefly,
patients were invited to participate in PROP UP if they were diag-
nosed with chronic HCV infection of any genotype; English-speak-
ing; age 21 years or older; and prescribed one of five DAA regimens.
For this analysis, we included data from a cohort of 961 patients
who had completed baseline surveys at the time of data retrieval
(11/28/2016).
2.4 | Measures
2.4.1 | PROMIS measures
The 10 PROMIS short forms included Fatigue-7a, Depression-8a,
Anger-5a, Anxiety-4a, Pain Interference-8a, Sleep Disturbance-8a,
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Applied Cognition-General Concerns-8a, Belly Pain-6, Diarrhea-6,
and Nausea/Vomiting-4 (available via www.HealthMeasures.net).
The short forms were used to measure symptoms most common or
salient to HCV or DAA therapy. Each PROMIS short form includes a
subset of items from a larger item bank that were the best perform-
ing items in terms of content validity and reliability.18,19 PROMIS
scores were scaled to standardized T-scores, with a mean of 50 and
standard deviation of 10 in the U.S. general population. An excep-
tion is Sleep Disturbance, which was normed on a clinical and gen-
eral population. Higher scores indicate worse symptoms. Studies in
other medical populations suggest that the minimally important dif-
ference within or between groups generally ranges from 2-5
points.24-27
2.4.2 | Headache impact test-6 (HIT-6)
Headaches have been reported as an adverse event during industry-
sponsored DAA trials,8-11 but no PROMIS instrument specifically
measures this symptom. Therefore, we used the 6-item Headache
Impact Test to measure headaches that could occur during treat-
ment.22 The six items are responded to on a 5-point Likert scale
ranging from “Never” to “Always.” The final score is summed and
can range from 36 to 78, with higher scores reflecting worse head-
aches.
2.4.3 | Memorial symptom assessment scale (MSAS)
The MSAS is a reliable and validated instrument used to evaluate
32 symptoms associated with common medical conditions treat-
ment.28,29 Many of these symptoms may be experienced by
patients with HCV or undergoing treatment. Participants first indi-
cate the presence or absence of the 32 symptoms, and if present,
then rate the symptom on three attributes (severity, frequency,
interference with functioning) on a scale of 1 to 4. Each total item
score ranges from 0 (if symptom is absent) to 4 (if present, the
average of three attributes). Higher scores indicate worse symp-
toms. In this study, we used the MSAS as a comparison legacy
measure (ie, a previously evaluated measure), using several symp-
tom item scores to evaluate convergent validity with specific PRO-
MIS surveys (eg, MSAS total pain score correlated with PROMIS
Pain Interference score). Patient data were excluded from the anal-
ysis if more than 13% of items were missing, as recommended by
the MSAS developers.28
2.4.4 | HCV-PRO
The HCV-PRO is a disease-specific survey that assesses well-being
and HRQOL in people with chronic HCV.30,31 The measure was
developed in accordance with the Food and Drug Administration
guidelines and demonstrates good reliability and validity and was
used as a second legacy measure. The survey includes 16 items with
responses ranging from “1 = all of the time’’ to “5 = none of the
time” with the sum transformed to a 0-100 scale. In contrast to the
other PRO measures, a higher HCV-PRO score indicates higher
HRQOL. In this study, we used several individual items from the
HCV-PRO to evaluate convergent validity with specific PROMIS
measures (eg, HCV-PRO item “feeling tired” correlated with PROMIS
Fatigue).
2.4.5 | Sociodemographics
Patients self-reported their age, sex, race, ethnicity, marital status,
education, and employment status.
2.4.6 | Number of health comorbidities
Patients completed a 35-item medical history form to indicate the
presence or absence of various common health conditions.
2.4.7 | Presence or absence of cirrhosis
Classification of cirrhosis status (Yes/No) was based on one or more
of the following source documents reviewed by trained study coor-
dinators at each site: Transient Elastography (eg, Fibroscan, Echo-
sens, Waltham, Massachusetts, USA), blood serum markers (eg,
FibroSure, Laboratory Corporation of America, Burlington, North
Carolina, USA)), and treating clinician’s impressions (based on cumu-
lative medical history, liver biopsy, ultrasound, procedures, physical
exam, laboratory tests). An expert hepatologist (M.W.F.) assisted
with cross-checking cirrhosis status with other variables in the data-
set to confirm classification, such as treatment duration and use of
ribavirin, laboratory values, and the following blood serum markers:
AST to platelet ratio index (APRI) > 2.0,32 FIB-4 score > 3.25,33 or
Model for End-Stage Liver Disease (MELD) score > 6.34 APRI > 2.0
and MELD > 6 are suggestive of cirrhosis, FIB-4 > 3.25 is suggestive
of advanced fibrosis, and MELD > 12 is suggestive of advanced cir-
rhosis.32,33
2.5 | Statistical analysis strategy
The internal consistency reliability of each measure was evaluated
using point- and interval-estimates of Cronbach’s alpha. We consid-
ered alpha > 0.70 to be an acceptable minimum criterion for estab-
lishing reliability in the cohort of patients studied.35,36 For
generalization from our sample to a target population, we infer relia-
bility in that population if the observed lower 95% confidence limit
for alpha exceeds 0.70.37 Due to the substantial number of partici-
pants who did not experience the symptom, the estimates of Cron-
bach’s alpha for the PROMIS Belly Pain, Diarrhea, and Nausea/
Vomiting were computed using only the data from participants who
reported the presence of that symptom because many patients did
not experience this symptom at all. In sensitivity analyses used to
evaluate the impact of this approach, the alpha estimates were also
computed based on all participants.
Ceiling and floor effects were evaluated in terms of the propor-
tion of participants who had the maximum score (or minimum
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score).38 Skewness and other properties of the frequency distribu-
tions of the scores were examined via graphical descriptive methods.
Factor-analytic assessment of structural validity (ie, underlying uni-
dimensionality) of each measure relied on unidimensional and multi-
dimensional graded-response item-response-theory models.39 Overall
model fit was evaluated based on the root mean square error of
approximation (RMSEA).40 An RMSEA value less than or equal to 0.06
was considered to indicate good fit, a value within 0.06-0.08 is a fairly
good fit, and a value above 0.10 is a poor fit.41 The S chi-square test
procedure was used to test the null hypothesis which states that the
item-level fit is adequate.42 Relative to longer questionnaires, shorter
questionnaires provide less power and precision to detect and quan-
tify item-level misfit. We assumed that item-level fit for the short-form
measures is similar to the item-level fit for long-form measures. The
standardized local dependence (LD) chi-square test procedure was
used to detect items that are excessively related after controlling for
the underlying domain: LD test statistic values larger than 10.0 identi-
fied items with substantial LD.43 In sensitivity analyses, to evaluate the
robustness of the main results to reasonable perturbation of the meth-
ods used, the LD tests were adjusted for multiple comparisons. Sensi-
tivity analyses also included an additional check on the underlying
dimensionality of the measure performed by fitting a bi-factor graded-
response item-response-theory modelwith each identified LD pair or
set of items as a second order factor.44 Any LD violations were
deemed negligible if they explained common variance (ECV) was at
least 0.90.45,46 ECV represents the variance explained by the general
factor in the bi-factor model.
To evaluate convergent validity, we used the absolute value of
point- and interval-estimates of the Spearman correlations (q)
between measures of theoretically-similar domains. For this purpose,
for each of the PROMIS and HIT-6 measures, we identified item
pairs which, logically, should be positively correlated. We anticipated
that there should exist substantial positive correlations between
those item pairs. We used Dancey and Reidy’s classification which
specifies that 0.40-0.70 is the range of a “moderate” correlation.47
Known-groups validity helps to support construct validity if it
can be demonstrated that an instrument discriminates between
groups that are known to differ on a given construct. The extant lit-
erature in HCV is extremely limited on definitive groups that would
differ according to precise symptoms. However, a few studies, though
not all suggest that HRQOL and one symptom, fatigue, may differ
among patients with and without cirrhosis.16,48-50 Based on this liter-
ature, the a priori analysis plan was to compare patients categorized
as cirrhotic or noncirrhotic based on medical chart review (as
described above). Secondarily, we used a three-category approach to
better observe PRO scores in patients with and without cirrhosis,
stratified by their baseline MELD scores: non-cirrhosis according to
medical chart review; MELD score 6-12; and MELD > 12. Thirdly,
based on findings from Rothrock et al, we evaluated potential
known-groups validity by exploring the association between the
number of health comorbidities as a continuous variable with symp-
tom scores, speculating that patients with more comorbid conditions
should experience greater symptoms.51
Unless otherwise specified, all statistical computations were per-
formed using SAS System software version 9.4 (SAS Institute, Cary,
NC). Analysis of the graded-response item-response-theory models
were performed using the SAS IRT procedure and using IRT-PRO
software, version 4.1 (Scientific Software International, Lincolnwood,
IL). PROMIS T-scores were computed using RSTUDIO software, version
1.0.136 (RStudio Inc.).
3 | RESULTS
3.1 | Patient characteristics
The characteristics of the 961 study participants at baseline are pre-
sented in Table 1. Mean age was 57 (SD = 10.7) years old. In addi-
tion to having chronic HCV and liver disease, participants reported
an average of 4 other health comorbidities (range 0-15).
3.2 | Missing values
The frequency of missing data among the HIT-6 and PROMIS short
form scores were less than 2.2%. The frequency of missing data for
the HCV-PRO score was 7.7%. We judged the reasons for the
incomplete data to satisfy the “missing completely at random” crite-
rion.52
TABLE 1 Patient characteristics (N = 961)
Na Mean (SD), Median Range
Age (y) 955 57 (10.7), 58 23-82
Number of comorbidities 961 4.1 (2.9), 4 0-15
Na Categories N (%)
Sex 951 Male 523 (55.0)
Female 428 (45.0)
Race 948 White 581 (61.3)
Black or African American 311 (32.8)
Other 56 (5.9)
Ethnicity 907 Not Hispanic or Latino 760 (83.8)
Hispanic or Latino 37 (4.1)
Other 110 (12.1)
Marital status 953 Married/in committed relationship 357 (37.5)
Single 345 (36.2)
Separated/Divorced/Widowed 251 (26.3)
Education 953 High school or equivalent diploma 527 (55.3)
Vocational school or higher 426 (44.7)
Employment 937 Unemployed/Disabled/Applying 460 (49.1)
Working full/part time 369 (39.4)
Retired/Homemaker/Student 108 (11.5)
Cirrhosis status 912 Present 456 (50.0)
Absent 456 (50.0)
SD, Standard deviation.
aN is the number of non-missing values. Missing data ranged from 0% to
5.6%; collectively only 1.5% of data values were missing.
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3.3 | Internal consistency reliability
Reliability of each of the symptom domains from the HIT-6, PROMIS
short forms, and HCV-PRO are presented in Table2. The HIT-6 and
HCV-PRO measures had high reliability (all Cronbach’s
alphas > 0.90). All PROMIS short forms, except the PROMIS Nau-
sea/Vomiting, yielded very good reliability estimates between 0.87
and 0.98.
3.4 | Floor and ceiling effects
Ceiling effects were consistently low among all PRO measures
( < 4% of participants had scores at the upper limit), suggesting that
all measures performed well in capturing severe symptoms at the
upper limits of the scales (Table 2). In contrast, many patients did
not report symptoms and therefore notable floor effects (range 30%
to 59%) were observed for the HIT-6 and a majority of the PROMIS
measures. Floor effects were small for PROMIS Fatigue (1.6%) and
Sleep Disturbance (6.8%) indicating that most patients reported at
least some mild fatigue and sleep disturbance problems. The HCV-
PRO had a negligible floor (0.10%) effect and a small ceiling effect
(5.9%).
3.5 | Structural validity
Findings supported the unidimensionality of the HIT-6, PROMIS
measures, and HCV-PRO (Table 3). Eight PRO measures had a
very good fit (RMSEA ≤ 0.06). None of the measures had a poor
fit (RMSEA > 0.10). The majority of the confirmatory factor
analysis models fitted to the measures produced high factor load-
ings ( > 0.70). Exceptions were noted for the PROMIS Fatigue,
Nausea/Vomiting and HCV-PRO, which showed multidimensional-
ity. The PROMIS Fatigue measure had a small factor loading
(0.30) for one item (“How often did you have enough energy to
exercise strenuously”). This item is the only item on the survey
that is reverse-scored and may explain why it did not hang
together with the other items. Nonetheless, a good fit was sug-
gested by the small RMSEA value of 0.04 and the absence of
local dependence (LD). The PROMIS Nausea/Vomiting survey and
HCV-PRO had items with factor loadings below 0.70 likely
because these measures tap into multiple constructs (eg, nausea
and vomiting). Despite this, the overall model fit was still very
good with RMSEA values < 0.06.
3.6 | Convergent validity
As shown in Table 4, both the HIT-6 score and the PROMIS Belly
Pain score were moderately correlated with the HCV-PRO item “I
felt bothered by pain or physical discomfort” and with the MSAS
pain score (range 0.37 to 0.48).
The PROMIS Pain Interference score was strongly correlated
with the HCV-PRO item “I felt bothered by pain or physical discom-
fort” (0.74) and MSAS pain score (0.76). PROMIS Fatigue, Sleep Dis-
turbance, and Cognitive Concerns were strongly correlated with
HCV-PRO items and MSAS scores of similar constructs (range 0.67
to 0.78). PROMIS Depression, Anger, Anxiety, and Diarrhea were
moderately correlated with specific HCV-PRO items and MSAS
scores of similar constructs (range 0.48 to 0.67). PROMIS Nausea/
TABLE 2 Reliability of the HIT-6, PROMIS short forms, and HCV-PRO (N = 961)
Measure N Items Alphaa 95% CIb N Floor (%)c Ceiling (%)c
HIT-6 scored 944 6 0.93 [0.92, 0.94] 944 30.9 0.2
PROMIS T-scoresd
Fatigue 941 7 0.87 [0.86, 0.88] 960 1.6 0.2
Pain interference 944 8 0.98 [0.98, 0.98] 961 36.7 3.9
Sleep disturbance 945 8 0.94 [0.93, 0.95] 960 6.8 2.5
Depression 942 8 0.96 [0.95, 0.96] 960 33.9 0.7
Cognitive concerns 940 8 0.96 [0.96, 0.97] 961 30.1 1.4
Anger 958 5 0.91 [0.91, 0.92] 961 18.3 1.0
Anxiety 954 4 0.91 [0.90, 0.92] 954 40.0 0.6
Belly paine 470 6 0.87 [0.85, 0.89] 960 49.7 0.1
Diarrheae 388 6 0.88 [0.87, 0.90] 948 58.5 0.3
Nausea/Vomitinge 452 4 0.63 [0.58, 0.69] 949 52.4 0.1
HCV-PROf 887 16 0.94 [0.94, 0.95] 887 0.1 5.9
aCronbach’s alpha coefficient.
b95% confidence interval (CI) for Cronbach’s alpha.
cProportion of responses at the minimum (floor) or maximum (ceiling) of the scale.
dHigher values of HIT-6 and PROMIS T-scores indicate more severe symptoms.
eOnly patients who reported presence of the symptom were analyzed.
fShown for reference in examining the properties of the HIT-6 and PROMIS scores. Higher values of HCV-PRO score indicate higher functional well-
being.
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Vomiting was moderately correlated with the MSAS vomiting and
nausea items (0.35 and 0.64, respectively).
3.7 | Known-groups validity
Differences in PRO scores between patients defined as noncir-
rhotic and cirrhotic via medical chart review were negligible (data
not shown). In a subsequent analysis (Tables 5 and 6) of three liver
disease categories (ie, noncirrhotic, MELD 6-12, MELD > 12), a
severity-response trend was observed such that worse symptoms
were associated with advancing liver disease. In particular, patients
with MELD > 12 had higher (worse) scores on all symptoms com-
pared to the other two groups, with mean differences ranging from
1.9 to 4.1. While the sample size of those with MELD > 12 was
small (n = 37) and provided limited precision, the mean differences
were comparable to established PROMIS minimally important differ-
ences reported in other medical populations.24-27 In the final known-
groups validity analysis, we found positive correlations between a
greater number of comorbid health conditions and worse symptom
scores, consistent with prior studies.51 Patients with more comorbid
conditions had worse scores on PROMIS Fatigue, Sleep Disturbance,
Pain Interference, and HRQOL on the HCV-PRO (moderate correla-
tions ranging from 0.39 to 0.53). Smaller positive correlations were
observed between the number of comorbid conditions and worse
scores on PROMIS Depression, Cognitive Concerns, Anger, Anxiety,
Belly Pain, Nausea, and HIT-6 (ranging from 0.29 to 0.34).
4 | DISCUSSION
The objectives of the current study were to establish the
reliability and validity of several PRO measures, specifically 10
PROMIS measures and the HIT-6, to evaluate specific symptoms in
patients with chronic HCV. Given the large national sample of
patients recruited for the PROP UP study, it represented a
reasonable platform in which to evaluate the psychometric
properties of several new PRO measures that could be useful in
future patient-centered outcomes research in the field of chronic
HCV. The overall findings from this study suggest that the
psychometric properties of these PROs are sufficiently satisfactory
to be used in future HCV studies, with specific caveats noted
below.
The internal consistency of the symptom scales was well above
the acceptable limit of 0.70 (range: 0.87-0.98) indicating very good
to excellent reliability. Only one exception was noted for the PRO-
MIS Nausea/Vomiting measure which appears to be multidimen-
sional. This measure had a lower reliability because its four items tap
three constructs (nausea, poor appetite, vomiting), which while asso-
ciated, are not highly correlated.
None of the PROs had notable ceiling effects, which is critically
important to investigations that need to capture very severe symp-
toms, as might be the case with patients listed for liver transplanta-
tion. Thus, these PROs are suitable to evaluate patients’ experiences
of severe and debilitating symptoms.
In contrast, floor effects were notable for most of the PROs,
with the exception of the HCV-PRO and PROMIS Fatigue and
Sleep Disturbance measures. Floor effects can be present when a
measure does not represent the full range of possible human
experiences, but we do not believe this to be the case with the
PROMIS and HIT-6 measures. Floor effects can also be evident
when the PRO score has both a binary component (presence or
absence of the symptom) and a continuous component represent-
ing the frequency or severity of a symptom, when present. In the
current sample of patients starting new DAA therapy, we would
anticipate that approximately half of these patients would be
asymptomatic for any one of the various symptom scales, thus
producing minimal scores and demonstrating sizable floor effects.
TABLE 3 Structural validity of the HIT-6, PROMIS short forms,
and HCV-PRO (N = 961)
Measure Items Factor loadingsa RMSEAb ECVc





Pain interference 8 0.95-0.98 0.09 0.96
Sleep disturbance 8 0.84-0.92 0.08 0.86
Depression 8 0.90-0.96 0.05 0.96
Cognitive Concerns 8 0.90-0.96 0.07 0.98
Anger 5 0.88-0.92 0.06 0.96
Anxiety 4 0.89-0.93 0.05 0.96
Belly pain 6 0.93-0.98 0.05 0.99
Diarrhea 6 0.83-0.98 0.07 0.87
Nausea/Vomiting 4 0.66g, 0.84-0.96 0.05 —e
HCV-PROh 16 0.55i, 0.67j,
0.71-0.86
0.04 0.82
aFactor loadings obtained from the unidimensional confirmatory factor
analysis. Factor loadings > 0.70 support unidimensionality.
bRMSEA, root mean square error approximation. RMSEA values ≤ 0.06
indicate good fit, values ≤ 0.08 are fair, and values above 0.10 generally
reflect poor fit. Statistics were based on full marginal tables. Model-
based weight matrix was used.
cECV, Expected Common Variance. ECV represents the variance
explained by the general factor in the bifactor model. ECV > 0.90 sup-
port unidimensionality.
dHigher values of HIT-6 and PROMIS T-scores indicate more severe
symptoms.
eUnidimensionality was assessed using a one-factor confirmatory factor
analysis.
fFactor loading of the item: “In the past 7 days, how often did you have
enough energy to exercise strenuously?”.
gFactor loading of the item: “In the past 7 days, how often did you have
a poor appetite?”.
hShown for reference in examining the properties of the HIT-6 and PRO-
MIS scores. Higher values of HCV-PRO score indicate higher functional
well-being..
iFactor loading of the item: “Having Hepatitis C affected my sex life”.
jFactor loading of the item: “Having Hepatitis C was very stressful to
me”.
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Floor effects occurred in this study because many patients did
not have the symptom: 59% reported no diarrhea, 52% reported
no nausea/vomiting, 50% reported no abdominal pain, and 37%
reported no pain. These floor effects are not surprising given that
half of the sample did not have cirrhosis and specific symptoms
(nausea/vomiting, abdominal pain) may not be present in patients
in the absence of advanced cirrhosis. Viewed from another per-
spective, these data indicate that 41-63% of patients actually do
experience mild to severe symptoms, representing a substantial
number of patients. One caveat for investigators who need to
capture subtle differences in symptoms in patients with mild dis-
ease, these PROs may lack sufficient sensitivity. Future studies
could evaluate if additional items from the PROMIS item banks
would increase variability in scores of patients with mild disease.
Additionally, a variety of statistical analysis methods designed for
measures that have both a binary component (presence or
absence) and continuous component may be useful; for example,
mixture models such as a zero-inflated log-normal model can be
applied for improved interpretability and precision.
The structural validity of the PROMIS surveys and the HIT-6
supported unidimensionality of most surveys, although not all.
Strong support for the unidimensionality for the HIT-6, and PROMIS
Depression, Cognitive Concern, Anger, Anxiety and Belly Pain scales
was observed. Some surveys tap multidimensional constructs (eg,
PROMIS Nausea/Vomiting), while other surveys may include an item
that does not hang together well with the other items (eg, PROMIS
Fatigue).
The assessment of convergent validity in this study focused on
the strength of correlation between the HIT-6 and PROMIS surveys
with theoretically-similar items from two previously validated legacy
measures: the HCV-PRO and the MSAS. Almost all surveys demon-
strated moderate (0.40-0.70) to strong ( > 0.70) correlations with
items tapping theoretically-similar constructs from the HCV-PRO
and MSAS, thus providing evidence that these instruments measure
the purported construct. These findings are consistent with another
recent psychometric study conducted in cirrhotic patients that docu-
mented satisfactory convergent and discriminant validity for the
same PROMIS measures.20 A few weak to moderate correlations
TABLE 4 Correlation of the HIT-6 and PROMIS short forms with HCV-PRO and MSAS items (N = 961)
Measure Corresponding measure Na Correlationb 95% CIc
HIT-6 scored HCV-PRO Item: I felt bothered by pain or physical discomfort 935 0.45 [0.39, 0.50]
MSASe pain score 936 0.37 [0.31, 0.43]
PROMIS T-scored
Fatigue HCV-PRO Item: I felt too tired during the day to get done what I needed 958 0.74 [0.70, 0.77]
MSAS lack of energy score 949 0.77 [0.74, 0.80]
Pain interference HCV-PRO Item: I felt bothered by pain or physical discomfort 951 0.74 [0.70, 0.77]
MSAS pain score 952 0.76 [0.73, 0.79]
Sleep disturbance HCV-PRO Item: I had difficulty sleeping or slept too much 954 0.74 [0.71, 0.78]
MSAS difficulty sleeping score 949 0.77 [0.75, 0.80]
Depression HCV-PRO Item: I felt downhearted and sad 951 0.67 [0.63, 0.71]
MSAS feeling sad score 949 0.64 [0.60, 0.68]
Cognitive concerns HCV-PRO Item: I was unable to think clearly or focus on my thoughts 957 0.78 [0.75, 0.81]
MSAS difficulty concentrating score 951 0.67 [0.64, 0.71]
Anger HCV-PRO Item: I felt restless or on edge 952 0.62 [0.58, 0.67]
MSAS feeling irritable score 943 0.58 [0.54, 0.63]
Anxiety HCV-PRO Item: Having Hepatitis C was very stressful to me 948 0.48 [0.43, 0.53]
MSAS feeling nervous score 941 0.56 [0.51, 0.61]
MSAS worrying score 939 0.61 [0.57, 0.66]
Belly pain HCV-PRO Item: I felt bothered by pain or physical discomfort 950 0.48 [0.42, 0.53]
MSAS pain score 951 0.39 [0.34, 0.45]
Diarrhea MSAS diarrhea score 937 0.51 [0.46, 0.57]
Nausea/ MSAS nausea score 939 0.64 [0.60, 0.69]
Vomiting MSAS vomiting score 940 0.35 [0.29, 0.40]
aThe number of participants with a non-missing value.
bAbsolute value of Spearman’s rank correlation coefficient between each measure and a similar construct.
c95% confidence interval (CI) for Spearman’s rank correlation coefficient.
dHigher values on the HIT-6 and PROMIS scores indicate more severe symptoms.
eMSAS, memorial symptom assessment scale; MSAS score, average of the three attributes: severity, frequency, and interference.
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were observed for the HIT-6 and PROMIS Belly Pain, which may be
because the general “pain” item we used to evaluate headache and
abdominal pain was too nonspecific. The absence of other legacy
measures or items impeded our ability to adequately examine
convergent validity for a couple of scales, representing one limitation
of this study.
Finally, we explored known-groups validity in patients with and
without cirrhosis, with varying levels of liver disease, and with a
range of comorbid medical conditions. Differences in PRO scores
were negligible between patients with no cirrhosis and mild cirrhosis,
however, patients with advanced cirrhosis (MELD > 12) had worse
symptom scores than patients with no or minimal cirrhosis, by 1.9 to
4.1 point differences. In particular, it is reasonable to expect that
gastrointestinal symptoms (nausea, abdominal pain, and diarrhea) and
pain would be worse in patients with advanced cirrhosis due to
decompensation compared to those with minimal or no cirrhosis
(point differences ≥ 3). This finding is consistent with Bajaj et al who
found differences between patients with compensated and decom-
pensated cirrhosis on several of the same PROMIS measures.20 The
lack of differentiation in this study between patients with no cirrho-
sis and those with mild cirrhosis may be because the former group
had stage 2-3 fibrosis, while the latter group had early stage 4 fibro-
sis; the small difference in liver disease stage may explain the similar-
ity in symptoms in these two groups. Unfortunately, liver disease
staging data are unavailable to substantiate this hypothesis, although
we know that at the time of enrollment into this study, many payers
only covered DAA therapy in patients with advanced fibrosis or cir-
rhosis. Future studies with the PROMIS measures could determine if
other items from the larger item banks could provide better differen-
tiation between these fibrosis levels. In a second analysis of know-
groups validity, we found evidence of an association between the
TABLE 5 Known-groups validity: PROs scores by liver disease status
Group A Group B
Measure
No cirrhosis N = 456a Cirrhosis (MELD 6-11) N = 334b Cirrhosis (MELD > 12) N = 37c Group A-Group Bd
Mean (SD) Mean (SD) Mean (SD) Mean difference (95% CI)
HIT-6 scoree 46 (11) 45 (10) 47 (11) 1.5 [4.9, 2.0]
PROMIS T-scorese
Fatigue 52 (11) 52 (11) 54 (10) 1.9 [5.6, 1.7]
Pain interference 53 (12) 53 (11) 56 (10) 3.0 [6.7, 0.7]
Sleep disturbance 52 (11) 52 (12) 54 (10) 2.4 [6.2, 1.4]
Depression 50 (11) 49 (11) 54 (9) 4.1 [7.6, 0.6]
Cognitive concerns 33 (9) 33 (9) 35 (8) 1.8 [4.9, 1.2]
Anger 49 (12) 48 (11) 51 (10) 2.9 [6.7, 0.8]
Anxiety 51 (11) 49 (10) 54 (10) 3.5 [6.9, 0.0]
Belly pain 37 (13) 37 (13) 40 (14) 3.3 [7.7, 1.1]
Diarrhea 36 (9) 35 (8) 39 (12) 3.8 [7.7, 0.2]
Nausea/Vomiting 42 (9) 42 (9) 46 (9) 3.9 [6.8, 1.0]
HCV-PROf 71 (23) 71 (23) 63 (23) 7.7 [0.0, 15.3]
SD, standard deviation; CI, confidence interval.
aSample size ranges from 415 to 456.
bSample size ranges from 312 to 334.
cSample size ranges from 36 to 37.
dGroup A, No cirrhosis or mild cirrhosis (MELD 6-12); Group B, Advanced Cirrhosis(MELD > 12).
eHigher values indicate more severe symptoms.
fHigher values indicate higher functional well-being.
TABLE 6 Known groups validity: Correlations between PRO
scores and Number of Comorbidities
Measure
Number of comorbidities
Spearman’s correlationa (95% CI)
HIT-6 scoreb 0.31 [0.25, 0.37]
PROMISb
Fatigue 0.39 [0.34, 0.44]
Pain interference 0.53 [0.48, 0.57]
Sleep disturbance 0.41 [0.36, 0.46]
Depression 0.30 [0.24, 0.36]
Cognitive concerns 0.33 [0.27, 0.38]
Anger 0.29 [0.23, 0.35]
Anxiety 0.30 [0.24, 0.36]
Belly pain 0.34 [0.28, 0.40]
Diarrhea 0.20 [0.14, 0.27]
Nausea/Vomiting 0.29 [0.23, 0.35]
HCV-PROc 0.48 [0.53, 0.43]
CI, confidence interval; Sample size ranges from 887 to 961.
aSpearman’s rank correlation coefficient (Rho).
bHigher values of HIT-6 and PROMIS T-scores indicate more severe
symptoms.
cHigher values indicate higher functional well-being.
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PROMIS measures and patients’ number of comorbidities, such that
patients with more comorbidities reported worse symptoms.51 These
analyses support known-groups validity by differentiating between
patients with varying degrees of comorbidities and liver disease.
The PROMIS measures, HIT-6, and HCV-PRO complement other
PROs that have been used to study the subjective experiences of
patients with HCV. A recent literature review identified 22 concepts,
almost all precise symptoms, described as important to patients that
have been inadequately examined in HCV clinical trials.5 Of 18 PRO
measures utilized in previous studies, only four were satisfactorily
developed and/or validated in patients with HCV, and three are
quality of life instruments. As for specific symptoms, only the Fatigue
Severity Scale had previously been validated in patients with HCV.53
Investigators can now use the current PROMIS and HIT-6 measures
to evaluate several additional precise symptoms that are important to
patients yet completely under-studied.
Our study has limitations that point to future directions for
improvements in PRO measurement in the field of HCV. All patients
were English speaking. Survey data were collected via various data
collection modalities and our limited data preclude evaluation of
social desirability or effects of data collection modality. Other legacy
instruments were not utilized in the parent study due to concern
about patient burden and could be an area of future investigation to
explore convergent and discriminant validity. Most of the PRO mea-
sures showed floor effects, ostensibly because many patients were
not experiencing a specific symptom. There is a chance that these
measures may not be sensitive enough to capture very mild side
effects of DAA therapy or subtle symptom improvement associated
with viral cure. However, investigators could seek to improve the
surveys by identifying additional items from the large PROMIS item
banks to create greater variability at the healthier end of the spec-
trum. Likewise, future studies might identify other items from the
PROMIS banks that help surveys better distinguish between patients
with no cirrhosis and early cirrhosis. There may be other symptoms
of HCV that were not evaluated in this study (eg, itching). These
PROs were chosen to capture a range of burdensome symptoms;
however it would be interesting to explore positive patient experi-
ences after being cured of HCV, that are not captured by these sur-
veys (eg, positive growth, psychological freedom, happiness) that are
not just the absence of symptoms, but altogether different human
experiences. Future studies might evaluate the responsiveness of the
PRO measures over time and in other patient subpopulations who
might have worse symptomatology (eg, patients with certain
sociodemographic characteristics or those with alcohol, drug use and
mental health issues).54-58
To conclude, the current study found the psychometric proper-
ties of 10 PROMIS short forms, the HIT-6, and the HCV-PRO per-
formed satisfactorily in patients with chronic HCV. Slight
modifications to the surveys may enhance performance among
healthy subjects and better distinguish between patients with and
without cirrhosis. Our study indicates that these symptom PROs can
be used in clinical research investigations of similar patients and clin-
ical settings.
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